CYP19A1 and metabolic syndrome: For example, aromatase inhibitors have been shown to be an effective and safer group of drugs for the first-line endocrine therapy of breast cancer [81], while HSD11B1 inhibitors are being explored as a potential strategy for managing conditions such as metabolic syndrome, diabetes, obesity, and inflammatory diseases [82].